Bausch, MSN Strike Deal Resolving Trulance Drug Patent Fight

By Editorial Team

Bausch Health Cos. and MSN Laboratories Private Ltd. have reached a settlement to end a nearly five-year dispute over patents related to the constipation drug Trulance. The resolution came after a bench trial in November.

Judge Stanley R. Chesler granted the joint request by Bausch, its Salix Pharmaceuticals Inc. unit, and MSN to dismiss all claims and defenses without prejudice. This order was issued on Monday in the US District Court for the District of New Jersey.

The parties sought the judge's approval in a filing on April 3, stating that they had reached a confidential settlement and license agreement. This agreement effectively puts an end to a legal battle that involved the consolidation of four patent-infringement lawsuits over MSN's proposed generic version of Trulance.

For more information and in-depth legal analysis, readers can access Bloomberg Law's coverage of this development.

© 2026 Bloomberg Industry Group, Inc. All Rights Reserved